CYBN

Cybin Inc

Jul 17 • 03:43PM ET

8.25

Dollar change +0.73
Percentage change 9.71	%

Healthcare • Biotechnology • Canada • AMEX

Peers: MNMD ATAI CMPS RLMD GHRS AVXL BTAI NBIX BHVN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.05	Insider Own	11.46%	Shs Outstand	21.60M	Perf Week	8.55%
Market Cap	190.00M	Forward P/E	-	EPS next Y	-2.93	Insider Trans	0.00%	Shs Float	20.39M	Perf Month	2.61%
Enterprise Value	96.19M	PEG	-	EPS next Q	-1.00	Inst Own	32.59%	Short Float	5.13%	Perf Quarter	7.14%
Income	-81.61M	P/S	-	EPS this Y	10.62%	Inst Trans	35.98%	Short Ratio	3.17	Perf Half Y	-6.57%
Sales	0.00M	P/B	1.08	EPS next Y	20.04%	ROA	-40.52%	Short Interest	1.05M	Perf YTD	-6.46%
Book/sh	7.63	P/C	2.03	EPS next 5Y	29.61%	ROE	-42.90%	52W High	13.88 -40.56%	Perf Year	-33.18%
Cash/sh	4.07	P/FCF	-	EPS past 3/5Y	31.02% -232.48%	ROIC	-49.52%	52W Low	4.81 71.52%	Perf 3Y	-62.13%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	3.88% 7.16%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	40.10%	Oper. Margin	-	ATR (14)	0.56	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.75	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	55.09	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.75	EPS Q/Q	-28.89%	SMA20	4.70%	Beta	-	Target Price	83.61
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	6.66%	Rel Volume	2.61	Prev Close	7.52
Employees	-	LT Debt/Eq	0.00	Earnings	Jul 01 BMO	SMA200	-4.74%	Avg Volume	329.42K	Price	8.25
IPO	Sep 13, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.97% -	Trades		Volume	824,465	Change	9.71%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-13-25	Initiated	Guggenheim	Buy	$35
Nov-19-21	Downgrade	Maxim Group	Buy → Hold

Today 07:30AM	Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder (Business Wire) +9.71%
Jul-16-25 09:46AM	3 High-Risk, High-Reward Stocks With Explosive Upside (MarketBeat)
Jul-01-25 11:19AM	REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures (Business Wire) +7.27%
Jun-30-25 10:03PM	Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights (Business Wire)
09:27PM	Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures (Business Wire)
04:08AM	Loading…
Jun-25-25 04:08AM	Cybin Granted Key Patent for CYB004 DMT Program, Supports GAD Treatment Development (Insider Monkey) +5.36%
Jun-19-25 10:10AM	Trump Trade: President said to weigh possible U.S. strike against Iran (TipRanks)
09:26AM	Psychedelic advocates hopeful Trump administration will support space, STAT says (TipRanks)
Jun-18-25 08:30AM	Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025 (Newsfile)
Jun-13-25 07:45AM	Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics (Business Wire)
Jun-12-25 07:30AM	Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference (Business Wire)
Jun-11-25 07:30AM	Cybin to Participate in the 2025 Psychedelic Science Conference (Business Wire)
Jun-03-25 07:30AM	Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder (Business Wire)
May-22-25 07:30AM	Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025 (Business Wire)
May-20-25 07:30AM	Cybin Applauds FDA Commissioner Dr. Martin Makarys Call to Accelerate and Prioritize Research on Psychedelic Therapeutics (Business Wire) -6.53%
07:30AM	Loading…
May-15-25 07:30AM	Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder (Business Wire)
May-14-25 07:30AM	Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase (Business Wire)
May-09-25 11:11AM	Psychedelic: Compass, GH Research, MindMed report quarterly earnings (TipRanks) +6.33%
May-08-25 07:30AM	Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder (Business Wire) +6.76%
May-01-25 07:30AM	Cybin to Participate at the 28th Annual Milken Institute Global Conference (Business Wire)
Apr-27-25 03:31PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Apr-25-25 11:30AM	Psychedelic: Clearmind completes clinical site initiations for AUD trial (TipRanks)
Apr-23-25 07:30AM	Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 (Business Wire)
Apr-21-25 08:00AM	Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs (Business Wire)
Mar-22-25 10:30AM	Psychedelic: Exclusive talk with biotech company Clearmind Medicine (TipRanks)
Mar-21-25 11:50AM	Psychedelic: atai Life Sciences, NRx report quarterly results (TipRanks)
Mar-14-25 11:40AM	Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial (TipRanks)
Mar-04-25 09:35AM	Cybin Inc. (CYBN) Loses -25.81% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Feb-28-25 11:30AM	Psychedelic: GH Research, Compass Pathways report earnings results (TipRanks)
Feb-17-25 09:55AM	Wall Street Analysts Think Cybin Inc. (CYBN) Could Surge 988.67%: Read This Before Placing a Bet (Zacks)
09:48PM	Loading…
Feb-10-25 09:48PM	Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights (Business Wire)
Jan-30-25 09:55AM	Wall Street Analysts Believe Cybin Inc. (CYBN) Could Rally 952.23%: Here's is How to Trade (Zacks)
Jan-15-25 12:07PM	Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder (Business Wire)
Jan-13-25 07:30AM	Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025 (Business Wire)
Jan-09-25 05:00PM	Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 (Business Wire)
Dec-10-24 07:30AM	Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results (Business Wire)
Dec-04-24 07:30AM	Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024 (Business Wire)
Nov-18-24 07:00AM	Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder (Business Wire) -8.62%
Nov-14-24 07:30AM	Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024 (Business Wire)
Nov-13-24 07:30AM	Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results (Business Wire) -10.26%
Oct-31-24 07:30AM	Cybin to Participate at the 2024 Milken Institute Future of Health Summit (Business Wire)
Oct-24-24 07:30AM	Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program (Business Wire)
Oct-03-24 07:30AM	Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024 (Business Wire)
Oct-01-24 07:30AM	Cybin Expands Clinical Team to Support CYB003 Phase 3 Program (Business Wire)
Sep-24-24 07:30AM	Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit (Business Wire)
Sep-19-24 05:38PM	Cybin Provides Corporate Update on Upcoming Clinical Milestones (Business Wire) +10.42% +7.24%
07:26AM	Cybin Announces Completion of Previously Announced Share Consolidation (Business Wire)
Sep-04-24 07:55AM	Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-27-24 07:01PM	Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation (Business Wire)
Aug-13-24 07:30AM	Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder (Business Wire)
Aug-08-24 07:36AM	Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights (Business Wire)
Aug-07-24 07:30AM	Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire)
Jul-08-24 08:38AM	A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update (Newsfile)
Jun-27-24 12:00PM	What Makes Cybin Inc. (CYBN) a New Buy Stock (Zacks)
Jun-26-24 07:41AM	Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights (Business Wire)
Jun-19-24 07:30AM	Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (Business Wire)
Jun-11-24 09:35AM	Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround (Zacks) +6.83%
07:30AM	Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development (Business Wire)
May-29-24 07:30AM	Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024 (Business Wire)
May-14-24 07:30AM	Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase (Business Wire)
May-06-24 08:32AM	Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones (Business Wire) +5.14%
Apr-25-24 07:30AM	Cybin to Participate at the 27th Annual Milken Institute Global Conference (Business Wire)
Apr-18-24 07:30AM	Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry (Business Wire)
Apr-16-24 07:30AM	Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder (Business Wire)
Apr-10-24 07:30AM	Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference (Business Wire) -5.90%
Mar-19-24 11:53AM	Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million (Business Wire)
Mar-18-24 07:30AM	Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas (Business Wire)
Mar-15-24 07:30AM	Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder (Business Wire) +7.23%
Mar-14-24 07:30AM	Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design (Business Wire)
Mar-13-24 07:00AM	Announces Oversubscribed Private Placement of U.S. $150 Million (Business Wire)
06:00AM	Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder (Business Wire)
Mar-12-24 10:37PM	Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003 (Business Wire) +10.28%
Feb-27-24 07:30AM	Cybin to Present at the TD Cowen 44th Annual Health Care Conference (Business Wire)
Feb-14-24 07:45AM	Cybin Reports Third Quarter Financial Results and Recent Business Highlights (Business Wire)
Feb-07-24 07:30AM	Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program (Business Wire) -9.06%
Jan-28-24 05:02PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jan-24-24 09:00AM	How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition (PR Newswire)
Jan-23-24 07:30AM	Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder (Business Wire)
Jan-08-24 07:34AM	Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028 (Business Wire)
Jan-04-24 07:32AM	Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs (Business Wire)
Dec-06-23 07:30AM	Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program (Business Wire)
Dec-05-23 07:30AM	Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results (Business Wire)
Nov-30-23 07:30AM	Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses (Business Wire) -6.03%
Nov-20-23 07:30AM	Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City (Business Wire)
Nov-16-23 07:30AM	Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023 (Business Wire)
Nov-15-23 07:30AM	Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting (Business Wire)
Nov-14-23 07:16PM	Cybin Reports Second Quarter Financial Results and Recent Business Highlights (Business Wire)
01:00PM	Cybin Announces Closing of Offering of Units Led by One of the Companys Largest Institutional Shareholders (Business Wire)
Nov-10-23 08:13AM	Canadian Investment Regulatory Organization Trade Resumption - CYBN (PR Newswire) -15.31%
08:05AM	Canadian Investment Regulatory Organization Trading Halt - CYBN (PR Newswire)
08:03AM	Cybin Announces up to US$64 Million Offering of Units (Business Wire)
Nov-03-23 07:40AM	Cybin to Participate at the 2023 Milken Institute Future of Health Summit (Business Wire)
Nov-01-23 03:32PM	Breakthrough Results: Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose - Comprehensive Topline Data Anticipated by Q4 2023 (Newsfile) -11.75%
07:30AM	Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline (Business Wire)
Oct-31-23 09:00AM	Cybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose - Full Topline Data on Track for Q4 2023 (PR Newswire) +6.71%
07:45AM	Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose (Business Wire)
Oct-29-23 05:17PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Oct-26-23 07:30AM	Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs (Business Wire) +12.61%
Oct-25-23 07:30AM	Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program (Business Wire) +11.10%
Oct-23-23 07:33AM	Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics (Business Wire)

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CYBN

Cybin Inc

Upgrade your FINVIZ experience